Business
Lucid Diagnostics Provides Business Update and Second Quarter Financial Results
Quarterly EsoGuard® test volume increased 20 percent sequentially and 159 percent annually Revenue cycle management upgrade completed with immediate positive
About this update from Lucid Diagnostics Inc.
[{"type":"text","content":"Quarterly EsoGuard® test volume increased 20 percent sequentially and 159 percent annually\nRevenue cycle management upgrade completed with immediate positive impact to claims processing and payments\nUnprecedented cancer and precancer detection results from an NCI-funded EsoGuard study released\nConference call and webcast to be held tomorrow, August 15th at 8:30 AM EDT\nNEW YORK, Aug. 14, 2023 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) (\"Lucid\" or the \"Company\") a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ( \"PAVmed\"), today provided a business update for the Company and presented financial results for the three and six months ended June 30, 2023.\n\n \n \n \n \n \n \n\n \nConference Call and Webcast\nThe webcast will take place on Tuesday, August 15, 2023, at 8:30 AM and will be accessible in the investor relations section of the Company's website at luciddx.com. Alternatively, to access the conference call by telephone, U.S.-based callers should dial 1-833-816-1418 and international listeners should dial 412-317-0511. All listeners should provide the operator with the conference call name \"Lucid Diagnostics Business Update\" to join.\nFollowing the conclusion of the conference call, a replay will be available for 30 days on the investor relations section of the Company's website at luciddx.com.\nBusiness Update Highlights\n\"Lucid closed out a strong first half of 2023, with yet another quarter of double-digit EsoGuard test volume growth and major accomplishments on multiple strategic fronts, which we believe will drive substantial value in the coming quarters\" said Lishan Aklog, M.D., Lucid's Chairman and Chief Executive Officer. \"Commercial execution underpinning the sustained test volume growth remained very strong, driven by steadily increasing per-seller productivity as well as expanding utilization of our satellite Lucid Test Center program and high-volume #CheckYourFoodTube testing events. The launch of our first mobile test unit and the execution of our first direct contract with an employer to offer EsoGuard testing as an employee benefit, reflect our relentless commitment to expanding EsoGuard access across all available channels.\"\n\"Key accomplishments critical to translating this commercial success into ...